Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Diabetes Care

• Publication date

  2000-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIACARE.23.5.644PMID 10834424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients.

  1999cited by this paper
• Long-acting insulin analogs.

  1999cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

  1998cited by this paper
• The Use of Areas Under Curves in Diabetes Research

  1995cited by this paper
• Receptor Binding and Tyrosine Kinase Activation by Insulin Analogues With Extreme Affinities Studied in Human Hepatoma HepG2 Cells

  1991cited by this paper
• The Action Profiles of Human NPH Insulin Preparations

  1989cited by this paper
• Somatostatin Impairs Clearance of Exogenous Insulin in Humans

  1987cited by this paper

• Molecular engineering of designer diabetes therapeutics.

  2026cites this paper
• Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

  2025cites this paper
• Improving owner compliance with therapy of canine and feline diabetes: the American perspective

  2025cites this paper
• Navigating Insulin Options for Diabetes Management.

  2025cites this paper
• Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta‐analysis of randomised controlled trials

  2025cites this paper
• Tirzepatide Versus Long-Acting Insulin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

  2025cites this paper
• Advancement of artificial intelligence based treatment strategy in type 2 diabetes: A critical update

  2025cites this paper
• BioJect: An in vitro platform to explore release dynamics of peptides in subcutaneous drug delivery.

  2025cites this paper
• An Overview of Currently Available Injectable Therapies in Diabetes: A Guide to Practitioners

  2025cites this paper
• Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers

  2025cites this paper
• Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus

  2024cites this paper
• Biotechnology Revolution Shaping the Future of Diabetes Management

  2024cites this paper
• Icodec ONWARDS: A review of the first once-weekly diabetes treatment for nurse practitioners and physician assistants

  2024cites this paper
• The triggering pathway, the metabolic amplifying pathway, and cellular transduction in regulation of glucose-dependent biphasic insulin secretion

  2024cites this paper
• The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

  2024cites this paper
• Icodec: A Novel Once-Weekly Basal Insulin for Diabetes Management

  2024cites this paper
• Insulin's Legacy: A Century of Breakthroughs and Innovation.

  2024cites this paper
• Massive insulin overdose in a dog requiring extended observation and management

  2023cites this paper
• A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

  2023cites this paper
• Injectable Systems for Long-lasting Insulin Therapy.

  2023cites this paper
• Commercially available injectables in diabetes – Insulin, incretins, and more

  2023cites this paper
• Current Status of Weekly Insulin Analogs and Their Pharmacokinetic/Pharmacodynamic Evaluation by the Euglycemic Clamp Technique

  2023cites this paper
• Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study

  2023cites this paper
• Structure and properties of insulin

  2022cites this paper
• How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers

  2022cites this paper
• Gluclas: A software for computer-aided modulation of glucose infusion in glucose clamp experiments

  2022cites this paper
• Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial

  2022cites this paper
• Insulin analogs in the treatment of type II diabetes and future perspectives.

  2022cites this paper
• early noughties - Treating to Target

  2022cites this paper
• Titration of Long-Acting Insulin Using Continuous Glucose Monitoring and Smart Insulin Pens in Type 1 Diabetes: A Model-Based Carbohydrate-Free Approach

  2022cites this paper
• Effects of Unsuppressed Endogenous Insulin on Pharmacokinetics and/or Pharmacodynamics of Study Insulin in the Healthy: A Retrospective Study

  2021cites this paper
• Si l'ère des insulines semi-synthétiques et biosynthétiques nous était contée

  2021cites this paper
• A Hundred Years of Insulin Innovation: When Science Meets Technology

  2021cites this paper
• Charting the next century of insulin replacement with cell and gene therapies.

  2021cites this paper
• The ongoing evolution of basal insulin therapy over 100 years and its promise for the future

  2021cites this paper
• One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus

  2021cites this paper
• Weekly Insulin Becoming a Reality

  2021cites this paper
• Requirements for Insulin Glargine 300 U / Ml for Patients with Type-1 Diabetes Mellitus Previously Treated with Insulin Glargine 100 U / Ml , According to the Number of Daily Injections Given Previously

  2021cites this paper
• All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK

  2021cites this paper
• HYPERGLYCEMIA ON THE BACKGROUND OF TREATMENT OF COVID-19-ASSOCIATED PNEUMONIA USING GLUCOCORTICOIDS

  2021cites this paper
• Prospektywna ocena skuteczności i bezpieczeństwa insuliny glargine 100 U / ml (Gla-100) u dorosłych chorych na cukrzycę w Polsce: badanie obserwacyjne LARE

  2021cites this paper
• Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials.

  2021cites this paper
• The Evolution of Insulin Administration in Type 1 Diabetes

  2021cites this paper
• Insulin Centennial: Milestones influencing the development of insulin preparations since 1922

  2021cites this paper
• Critical Low Catastrophe: A Case Report of Treatment-Refractory Hypoglycemia following Overdose of Long-Acting Insulin

  2020cites this paper
• (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

  2020cites this paper
• Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?

  2020cites this paper
• Proportion and clinical profile of type 1 diabetes patients with a clinical time‐action of insulin glargine U100 shorter than 24 hours

  2020cites this paper
• Challenges of the intensive insulin therapy in experimental models of extensive burn injury

  2020cites this paper
• Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients

  2020cites this paper
• Factors Influencing Insulin Absorption Around Exercise in Type 1 Diabetes

  2020cites this paper
• Case Report: High-concentration Insulin Glargine Overdose Complicated by Hepatic Steatosis

  2020cites this paper
• Injectable Systems for Long-Lasting Insulin Therapy

  2019cites this paper
• The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control

  2019cites this paper
• Fiches cliniques

  2019cites this paper
• Thérapeutique des désordres glycémiques

  2019cites this paper
• Lilly Insulin Glargine Versus Lantus® in Type 2 Diabetes Mellitus Patients: India and East Asia Subpopulation Analyses of the ELEMENT 5 Study

  2019cites this paper
• Comment on Law et al. Suboptimal Nocturnal Glucose Control Is Associated With Large for Gestational Age in Treated Gestational Diabetes Mellitus. Diabetes Care 2019;42:810–815

  2019cites this paper
• Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review

  2019cites this paper
• Assessment of Safety and Effectiveness of Glaritus® (Wockhardt’s Insulin Glargine) in a Prospective, Multi-Centric Post Marketing Observational Study in Nepalese Having Type 2 Diabetes Mellitus

  2019cites this paper
• Insulin analogs: Glimpse on contemporary facts and future prospective

  2019cites this paper
• Welchen Stellenwert haben Insulinanaloga in der Behandlung des Diabetes?

  2019cites this paper
• Lilly Insulin Glargine Versus Lantus® in Insulin-Naïve and Insulin-Treated Adults with Type 2 Diabetes: A Randomized, Controlled Trial (ELEMENT 5)

  2019cites this paper
• Detemir vs Glargine: Comparison of Inpatient Glycemic Control

  2019cites this paper
• Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins

  2019cites this paper
• Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia

  2019cites this paper
• (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.

  2019cites this paper
• Why might pumps fail in pregnant women with Type 1 diabetes?

  2019cites this paper
• Modeling Ketogenesis for Use in Pediatric Diabetes Simulation

  2019cites this paper
• Préparations insuliniques au cours de la dernière décennie.

  2018cites this paper
• A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

  2018cites this paper
• Effects of Glargine Insulin on Glycemic Control in Patients with Diabetes Mellitus Type II Undergoing Off-pump Coronary Artery Bypass Graft

  2018cites this paper
• Switching From Pre-mixed Insulin to Regimens with Insulin Glargine in Type 2 Diabetes: A Prospective, Observational Study of Data From Adriatic Countries

  2018cites this paper
• Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy for the Treatment of Type 2 Diabetes: Are Two Agents Better Than One?

  2018cites this paper
• Insulin Glargine 100 Units/mL Alone or in Combination with Short-Acting Insulin in the Management of Uncontrolled Type 2 Diabetes Mellitus: A Prospective Real-Life Study from Egypt (DIAMOND)

  2018cites this paper
• Update on newer antidiabetic drugs in clinical practice

  2018cites this paper
• Glycemic Control in Hospitalized Patients with Diabetes Receiving Corticosteroids Using a Neutral Protamine Hagedorn Insulin Protocol: A Randomized Clinical Trial

  2018cites this paper
• Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs

  2018cites this paper
• A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part one: The principles of glucose clamp studies

  2018cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• Influence of Human Biorhythms on the Blood Glucose Level and the Efficacy of Hypoglycemic Drugs (Review)

  2017cites this paper
• Gli analoghi dell ’ insulina nel trattamento di bambini e adolescenti con diabete mellito tipo 1

  2017cites this paper
• Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

  2017influential citation
• Safety of Degludec versus Glargine in Type 2 Diabetes.

  2017cites this paper
• Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?

  2017cites this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial

  2017cites this paper
• Effectiveness and safety of basal-bolus therapy (insulin glargine+insulin glulisine) in patients with type 1 diabetes previously uncontrolled on any insulin regimen: multinational phase-IV study

  2017cites this paper
• Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study

  2017cites this paper
• LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels

  2017cites this paper
• Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial

  2017cites this paper
• Application of Premixed Insulin NovoMix®30 and NovoRapid® as Multiple Daily Injections or as Basal Bolus Format in Selected Diabetic Patients: Practical Evidence from Prospective Case Series

  2017cites this paper
• Practical use of insulin in diabetes mellitus

  2017cites this paper
• Glargine Insulin Use Versus Continuous Regular Insulin in Diabetic Surgical Noncritically Ill Patients Receiving Parenteral Nutrition: Randomized Controlled Study

  2017cites this paper
• Light Control of Protein Solubility Through Isoelectric Point Modulation.

  2017cites this paper
• Polymorphic distribution of proteins in solution by mass spectrometry: The analysis of insulin analogues.

  2017cites this paper
• Safety of Degludec versus Glargine in Type 2 Diabetes.

  2017cites this paper
• Using premixed biphasic insulin analogs humalog® mix 25 and humalog® mix 50 in basal bolus format: evidence from research, clinical practice and case reports

  2017cites this paper
• Enjeux et freins à l’utilisation du premier biosimilaire de l’insuline glargine en milieu hospitalier

  2017cites this paper
• The past, present, and future of basal insulins

  2016cites this paper
• Update on the treatment of type 2 diabetes mellitus.

  2016cites this paper